Objective: To evaluate the effectiveness of ultrasound-guided radiofrequency (RF) ablation in patients with incompletely treated hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE) and to evaluate possible prognostic factors for this therapy.
Subjects And Methods: Thirty nine patients with incompletely treated single HCC (≤ 5 cm) after TACE were treated with RF ablation. All patients were evaluated for complete tumor ablation rate, local recurrence-free rate, overall survival rate, and complications. Local recurrence-free rate and overall survival rate were calculated using the Kaplan-Meier method. The possible prognostic factors of local recurrence-free rate and survival rate were analyzed using Cox proportional-hazards regression model.
Results: The complete tumor ablation rate was 92.3%. Local recurrence-free rates for 1-, 2-, 3-, and 5-years were 81.7%, 63.1%, 53.6%, and 35.7%, respectively. One-, 2-, 3-, and 5-year overall survival rates were 96.9%, 82.9%, 67.8%, and 48.4%, respectively. Among prognostic factors included in the analysis, only tumor diameter (≤ 2 cm versus > 2 cm) was statistically significant in terms of predicting local recurrence. Complications were observed in two patients, one with liver abscess and the other with portal venous thrombosis.
Conclusion: Ultrasound-guided RF ablation could be effective and safe in treating incompletely treated HCC after TACE. The diameter of HCC was a significant prognostic factor for local recurrence.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341453 | PMC |
http://dx.doi.org/10.3348/kjr.2012.13.S1.S104 | DOI Listing |
J Hand Surg Eur Vol
January 2025
Hand & Wrist Unit, Genolier Campus, Vaud, Switzerland.
Total wrist arthrodesis can be used to treat symptomatic end-stage wrist osteoarthritis after failed conservative treatment. It can also be considered the last-resort option when partial fusion, proximal row carpectomy, denervation or prosthetic arthroplasty is unsuccessful. Currently anatomic pre-contoured low-profile plates with angle stable screws are available with or without inclusion of the carpometacarpal joints.
View Article and Find Full Text PDFJMIR Res Protoc
January 2025
Department of Psychiatry, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Background: Psychotherapy is central to the treatment of mental disorders, highlighting the importance of medical students and residents developing competencies in this area. Chinese medical residents have expressed a strong need for psychotherapy training, yet they are generally dissatisfied with the current offerings. This paper presents the protocol for an evidence-based, well-structured psychotherapy teaching program aimed at medical students and residents.
View Article and Find Full Text PDFAnn Hematol
January 2025
Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325035, China.
Background: Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is often refractory and relapsing, leading to increased mortality post-HSCT.
Methods: We retrospectively analyzed the cases of patients with transfusion-dependent β-thalassemia (TDT) who underwent allo-HSCT to study their clinical features, the occurrence of AIHA post-HSCT, and treatment response and to explore the possible pathogenesis of AIHA.
Result: A total of 113 patients were registered in the study, out of whom 14 developed AIHA following allo-HSCT, resulting in a cumulative incidence of 12.
Alzheimers Dement
December 2024
McLaughlin Research Institute, Great Falls, MT, USA.
Background: Apolipoprotein E (ApoE) is a lipid cargo binding protein that has three variants in humans, ApoE 2, 3, and 4. The ApoE 4 allele is the greatest known genetic factor for sporadic Alzheimer's Disease. The gut microbiome (GMB) is a key essential to health, and bacterial dysbiosis can lead to poorer outcomes for disease states and an increase in microbiota and their metabolites in the peripheral.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of British Columbia, Vancouver, BC, Canada.
Background: Antibodies targeting amyloid beta (Aß) have recently been developed as promising treatments for Alzheimer's Disease (AD). Aducanumab was the first to receive limited FDA approval in 2021 offering much needed new treatment options for AD patients. Aducanumab clears aggregated Aß in the brain, presumably through microglial phagocytosis, although the exact cellular and molecular mechanisms of its effect remain incompletely understood.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!